Yet Another Research Firm has Initiated Coverage on Kezar Life Sciences (KZR)

July 16, 2018 - By Matthew Richard

How Jefferies Currently Rates Kezar Life Sciences (KZR)

Analysts at Jefferies initiated coverage Kezar Life Sciences (KZR) shares in analysts report sent to investors and clients on Monday morning, IR.net reports. The company has set a “Buy” rating on KZR stock.

The stock increased 2.09% or $0.33 during the last trading session, reaching $16.13. About 59,995 shares traded. Kezar Life Sciences, Inc. (KZR) has 0.00% since July 16, 2017 and is . It has underperformed by 12.57% the S&P500.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. The company has market cap of $307.62 million.

More notable recent Kezar Life Sciences, Inc. (NASDAQ:KZR) news were published by: 247Wallst.com which released: “IPO News This Week: A Record 12 IPOs Coming to Market” on June 24, 2018, also Nasdaq.com with their article: “Retailers, Markets React To Supreme Court Ruling On Online Sales Taxes” published on June 21, 2018, Bizjournals.com published: “Kezar Life Sciences stock jumps 18% after IPO raises $75M” on June 21, 2018. More interesting news about Kezar Life Sciences, Inc. (NASDAQ:KZR) were released by: Investorplace.com and their article: “8 Biotech Stocks With IPOs This Week” published on June 20, 2018 as well as Seekingalpha.com‘s news article titled: “Premarket analyst action – healthcare” with publication date: July 16, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.